Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Centessa Pharmaceuticals plcNASDAQ: CNTA
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 19.4% from a year ago
Short-term investments stood at $214.16M at the end of Q1 FY2026, up 19.4% from a year earlier and down 8.2% from the prior quarter.
Context
- Short-term investments amounted to 33.4% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +19.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 233.28M USD
- Year-over-year change
- +135.7%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 233.28M | +135.7% |
| FY2024 | 2024-12-31 | 98.96M | -23.0% |
| FY2023 | 2023-12-31 | 128.52M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +19.4% is the 5th highest of 8, against a peer median of +50.6%.
- Short-term investments amounts to 33.4% of total assets for CNTA, versus a peer median of 23.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $956.21M USD | +50.6% | +134.1% | 91.4% | |
| Sep 2026 | $868.24M USD | +142.7% | -13.2% | 72.4% | |
| Jun 2026 | $866.36M USD | +127.3% | — | 64.9% | |
| Jun 2026 | $572M USD | +368.7% | +24.2% | 69.1% | |
| Sep 2026 | $391.8M USD | -45.1% | -42.0% | 23.3% | |
| Mar 2026 | $238M USD | -35.2% | -25.0% | 18.4% | |
| Jun 2026 | $222.36M USD | +11.8% | +37.3% | 22.4% | |
| Mar 2026 | $214.16M USD | +19.4% | — | 33.4% | |
| Jun 2026 | $10M USD | — | — | 0.9% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥0 CNY | — | — | 0.0% |
| Peer median (excluding CNTA) | — | +50.6% | +5.5% | 23.3% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 595.08M | 393.64M | 128.03M | 383.22M | 61.3M |
| Short-term Investments | 0 | 0 | 128.52M | 98.96M | 233.28M |
| Net Receivables | 16.81M | 26.72M | 39.15M | 45.3M | 60.34M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 993K | 3.27M | 1.62M | 1.78M | 1.83M |
| Total Current Assets | 628.77M | 437.75M | 315.09M | 536.41M | 367.88M |
| Property, Plant & Equipment (Net) | 162K | 1.17M | 12.95M | 11.76M | 10.85M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 282.55M |
| Tax Assets | 0 | 3.51M | 29.65M | 26.59M | 24.78M |
| Other Non-current Assets | 699K | 1.88M | 2.55M | 2.05M | 1.44M |
| Total Non-current Assets | 861K | 6.56M | 45.15M | 40.39M | 319.62M |
| Total Assets | 629.64M | 444.31M | 360.25M | 576.8M | 687.5M |
| Account Payables | 8.07M | 13.84M | 11.82M | 7.14M | 7.58M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 769K | 1.58M | 112K | 835K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.97M | 7.95M | 839K | 10.18M | 35.35M |
| Total Current Liabilities | 24.64M | 38.34M | 39.39M | 58M | 42.94M |
| Long-term Debt | 75.7M | 69.8M | 75.7M | 108.94M | 7.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 37.74M | 0 | 29K | 29K | 110.12M |
| Total Non-current Liabilities | 113.44M | 69.8M | 84.62M | 117.26M | 117.7M |
| Total Liabilities | 138.08M | 108.14M | 124M | 175.25M | 160.63M |
| Common Stock | 252K | 265K | 273K | 359K | 405K |
| Retained Earnings | (385.65M) | (601.86M) | (752.95M) | (988.7M) | (1.19B) |
| Accumulated OCI | 688K | (1.5M) | 1.49M | 4.21M | 2.71M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 491.55M | 336.17M | 236.24M | 401.55M | 526.86M |
| Total Debt | 75.7M | 69.8M | 84.59M | 117.23M | 7.57M |
| Net Debt | (519.38M) | (323.84M) | (43.44M) | (266M) | (53.73M) |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.